The uniform minimum variance unbiased estimator (UMVUE) is, by definition, a solution to removing bias in estimation following a multi-stage single-arm trial with a primary dichotomous outcome. However, the UMVUE is known to have large residual mean squared error (RMSE). Therefore, we develop an optimisation approach to finding estimators with reduced RMSE for many response rates, which attain low bias. We demonstrate that careful choice of the optimisation parameters can lead to an estimator with often substantially reduced RMSE, without the introduction of appreciable bias
To improve the understanding of the appropriate design of phase II oncology clinical trials, we comp...
Phase II oncology trials are carried out to assess whether an experimental anti-cancer treatment sho...
To efficiently and completely correct for selection bias in adaptive two-stage trials, uniformly min...
The uniform minimum variance unbiased estimator (UMVUE) is, by definition, a solution to removing bi...
Phase II/III clinical trials are efficient two‐stage designs that test multiple experimental treatme...
Seamless phase II/III clinical trials offer an efficient way to select an experimental treatment and...
Seamless phase II/III clinical trials offer an efficient way to select an experimental treatment and...
In the development of a new treatment in oncology, phase II trials play a key role. On the basis of ...
The need for a more efficient drug development process led to migration from the traditional fixed-s...
International audienceABSTRACT: BACKGROUND: Simon's two-stage designs are widely used for cancer pha...
A common problem faced in clinical studies is that of estimating the effect of the most effective (e...
Recent FDA guidance on adaptive clinical trial designs defines bias as “a systematic tendency for th...
Recent FDA guidance on adaptive clinical trial designs defines bias as “a systematic tendency for th...
Recently, several study designs incorporating treatment effect assessment in biomarker‐based subpopu...
Adaptive designs can improve the efficiency of drug development, but further research is needed befo...
To improve the understanding of the appropriate design of phase II oncology clinical trials, we comp...
Phase II oncology trials are carried out to assess whether an experimental anti-cancer treatment sho...
To efficiently and completely correct for selection bias in adaptive two-stage trials, uniformly min...
The uniform minimum variance unbiased estimator (UMVUE) is, by definition, a solution to removing bi...
Phase II/III clinical trials are efficient two‐stage designs that test multiple experimental treatme...
Seamless phase II/III clinical trials offer an efficient way to select an experimental treatment and...
Seamless phase II/III clinical trials offer an efficient way to select an experimental treatment and...
In the development of a new treatment in oncology, phase II trials play a key role. On the basis of ...
The need for a more efficient drug development process led to migration from the traditional fixed-s...
International audienceABSTRACT: BACKGROUND: Simon's two-stage designs are widely used for cancer pha...
A common problem faced in clinical studies is that of estimating the effect of the most effective (e...
Recent FDA guidance on adaptive clinical trial designs defines bias as “a systematic tendency for th...
Recent FDA guidance on adaptive clinical trial designs defines bias as “a systematic tendency for th...
Recently, several study designs incorporating treatment effect assessment in biomarker‐based subpopu...
Adaptive designs can improve the efficiency of drug development, but further research is needed befo...
To improve the understanding of the appropriate design of phase II oncology clinical trials, we comp...
Phase II oncology trials are carried out to assess whether an experimental anti-cancer treatment sho...
To efficiently and completely correct for selection bias in adaptive two-stage trials, uniformly min...